Drug Profile
Luxeptinib - Aptose Biosciences/CrystalGenomics
Alternative Names: CG-026806; CG-806Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator CrystalGenomics
- Developer Aptose Biosciences; CrystalGenomics
- Class Antineoplastics; Fluorobenzenes; Imidazoles; Isoindoles; Phenylurea compounds; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Apoptosis stimulants; Aurora kinase inhibitors; Discoidin domain receptor 2 antagonists; Extracellular signal-regulated MAP kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Interleukin 6 inhibitors; Lyn protein-tyrosine kinase inhibitors; NLRP3 protein inhibitors; Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-akt inhibitors; Src-Family kinase inhibitors; Syk kinase inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Preclinical Mantle-cell lymphoma
- No development reported Haematological malignancies
Most Recent Events
- 26 Mar 2024 Aptose plans a phase II and phase III trials (Combination therapy) in 2H 2025
- 26 Mar 2024 Luxeptinib - Aptose Biosciences/CrystalGenomics is available for licensing as of 26 Mar 2024. https://www.aptose.com/
- 05 Apr 2023 Aptose Biosciences has patent protection for compounds including CG 806, pharmaceutical compositions comprising CG 806, and methods of their use for treating various diseases in USA and Europe